Key Drivers
- High gross margin
- Strong cash flow
- Rich valuation
AIAI Summary
KNSA has re-rated from a biotech story into a high-margin, cash-generating commercial franchise with ARCALYST driving a raised 2026 outlook, but the stock now depends on sustaining that growth while KPL-387 proves it can reduce single-product concentration, making any slowdown in ARCALYST or Phase 3 setback the main de-risking threat.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Strong cash flow
- •Rich valuation
KNSA shows strong profitability, cash generation, and liquidity with minimal debt, but its rich valuation and high operating spend leave limited upside and make the stock sensitive to any slowdown.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Higher lows
- •Volatile pullback
KNSA remains constructive over the last month, holding above its breakout zone with higher lows, but the fast, volatile rally raises near-term pullback risk unless it clears $80.92.
Sharp run-up into 2026-07-29 followed by a pullback into 2026-08-03 increased short-term volatility risk
Sentiment & News
Key News Insights:
- •ARCALYST growth
- •Guidance raised
- •Pipeline progress
Kiniksa delivered a strong Q2 with ARCALYST revenue surging 55%, lifted 2026 guidance, advanced KPL-387 to Phase 3, and entered the post-earnings period with improving estimate revisions.
The update is likely bullish for KNSA, reinforcing near-term revenue momentum and longer-term pipeline upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings